Domestic Antibody Treatment 'Rekkirona-ju'... Supplied to Medical Institutions from Mid-February

[Asia Economy Reporter Chunhee Lee] 'Rekkironaju,' a COVID-19 antibody treatment developed domestically, will be supplied to medical institutions starting mid-this month.

The Central Disease Control Headquarters (CDCH) announced on the 6th that the government will temporarily purchase Rekkironaju (active ingredient Regdanvimab·CT-P59) directly and supply it to medical institutions from mid-February.

The Ministry of Food and Drug Safety (MFDS) officially approved Rekkironaju, developed by Celltrion, as a COVID-19 antibody treatment the day before.

The CDCH stated that since it takes time to prepare product supply, the government will temporarily supply the treatment directly, and once a supply system between medical institutions and pharmaceutical companies is established, inconvenience in use will be minimized.

Rekkironaju will be administered only to those approved by the MFDS.

When approving Rekkironaju, the MFDS designated its use for mild patients aged 60 or older or those with one or more underlying conditions such as cardiovascular disease, chronic respiratory disease, diabetes, or hypertension, as well as patients with pneumonia requiring oxygen therapy.

Each medical institution can use Rekkironaju within 7 days from the onset of symptoms for these patients.

This content was produced with the assistance of AI translation services.